Gao Y, Cheng AL, Li LX, Parent N, et al. Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. Int J Cancer 2025 Mar 13. doi: 10.1002/ijc.35407.
PMID: 40079683